RecruitingNot ApplicableNCT06701084

Molecular Genetic Mechanisms of Infantile Epilepsies and the Impact of Genetic Diagnosis

Molecular Genetic Mechanisms of Infantile Epilepsies and the Impact of Genetic Diagnosis: Gene-Shortening Time of Evaluation in Pediatric Epilepsy Services (Gene-STEPS)


Sponsor

Boston Children's Hospital

Enrollment

600 participants

Start Date

Sep 2, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this study is to discover new genetic causes of infantile epilepsies and evaluate the impact of these discoveries on infants with epilepsy and their families.


Eligibility

Inclusion Criteria4

  • Infant Criteria
  • Seizure onset at less than 12 months of age
  • Enrollment within 6 weeks of seizure-related presentation
  • Patient at Boston Children's Hospital

Exclusion Criteria5

  • Simple febrile seizures
  • Acute provoked seizures (e.g., due to sepsis, hemorrhage, electrolyte abnormality, cerebral infarction, hypoxic ischemic encephalopathy, non-accidental injury)
  • Genetic or acquired cause of epilepsy already identified, including brain magnetic resonance imaging findings consistent with a specific genetic etiology (e.g., tuberous sclerosis complex)
  • Deceased prior to enrollment
  • \- Not the legal guardian of the eligible infant

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICGenomic Sequencing

Genomic sequencing data will be comprehensively analyzed for pathogenic variants that explain the participants epilepsy.


Locations(1)

Boston Children's Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06701084